Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

A head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive non-small cell lung cancer could help oncologists fine-tune first-line TKI selection beyond what’s been seen in clinical trials alone, according to a study conducted by a team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan and quality of life for many patients.

May 15, 2026

Vol.52 No.19

Clinical Roundup

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Diaceutics has released research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer in the U.S. are still not receiving the most appropriate treatment.

May 01, 2026

Vol.52 No.17

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

Sen. Susan Collins and patient advocate Jill Feldman are recognized with AACR Distinguished Service Awards

The American Association for Cancer Research will honor leaders from government and the advocacy community with awards for distinguished service in support of cancer research at the AACR Annual Meeting 2026 to be held April 17-22 in San Diego.

April 17, 2026

Vol.52 No.15

Clinical Roundup

E-cigarette taxes reduce vaping; no increase in adult smoking, OSU study finds

For years, a central debate in tobacco policy has been whether taxing e-cigarettes might unintentionally drive vapers back to traditional cigarettes.

April 17, 2026

Vol.52 No.15

Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

YOU MAY BE INTERESTED IN

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Sen. Susan Collins and patient advocate Jill Feldman are recognized with AACR Distinguished Service Awards

E-cigarette taxes reduce vaping; no increase in adult smoking, OSU study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

YOU MAY BE INTERESTED IN

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Sen. Susan Collins and patient advocate Jill Feldman are recognized with AACR Distinguished Service Awards

E-cigarette taxes reduce vaping; no increase in adult smoking, OSU study finds

Never miss an issue!

Login

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”